The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

The FDA granted the approval of Hympavzi to Pfizer Inc.